Our findings are in line with those of Chang et al, who showed the enhancement of tumor hypoxia and decrease in the number of microvessels after 3 days of sorafenib treatment in VHL mutant 786-O ccRCC xenografts (26). This evidence concerns the gene VHL and nonpapillary renal cell carcinoma.